RYTM
Price
$95.89
Change
-$2.03 (-2.07%)
Updated
Nov 13 closing price
Capitalization
6.4B
110 days until earnings call
Intraday BUY SELL Signals
TARS
Price
$72.53
Change
-$2.28 (-3.05%)
Updated
Nov 13 closing price
Capitalization
3.07B
122 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

RYTM vs TARS

Header iconRYTM vs TARS Comparison
Open Charts RYTM vs TARSBanner chart's image
Rhythm Pharmaceuticals
Price$95.89
Change-$2.03 (-2.07%)
Volume$862K
Capitalization6.4B
Tarsus Pharmaceuticals
Price$72.53
Change-$2.28 (-3.05%)
Volume$354.55K
Capitalization3.07B
RYTM vs TARS Comparison Chart in %
RYTM
Daily Signal:
Gain/Loss:
TARS
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RYTM vs. TARS commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RYTM is a Hold and TARS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (RYTM: $97.92 vs. TARS: $74.81)
Brand notoriety: RYTM and TARS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RYTM: 106% vs. TARS: 52%
Market capitalization -- RYTM: $6.4B vs. TARS: $3.07B
RYTM [@Biotechnology] is valued at $6.4B. TARS’s [@Biotechnology] market capitalization is $3.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $110.25B to $0. The average market capitalization across the [@Biotechnology] industry is $2.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RYTM’s FA Score shows that 1 FA rating(s) are green whileTARS’s FA Score has 0 green FA rating(s).

  • RYTM’s FA Score: 1 green, 4 red.
  • TARS’s FA Score: 0 green, 5 red.
According to our system of comparison, TARS is a better buy in the long-term than RYTM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RYTM’s TA Score shows that 4 TA indicator(s) are bullish while TARS’s TA Score has 4 bullish TA indicator(s).

  • RYTM’s TA Score: 4 bullish, 5 bearish.
  • TARS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, TARS is a better buy in the short-term than RYTM.

Price Growth

RYTM (@Biotechnology) experienced а -1.56% price change this week, while TARS (@Biotechnology) price change was +9.69% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.51%. For the same industry, the average monthly price growth was -3.12%, and the average quarterly price growth was +61.90%.

Reported Earning Dates

RYTM is expected to report earnings on Mar 04, 2026.

TARS is expected to report earnings on Mar 16, 2026.

Industries' Descriptions

@Biotechnology (+1.51% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RYTM($6.4B) has a higher market cap than TARS($3.07B). RYTM YTD gains are higher at: 74.920 vs. TARS (35.109). TARS has higher annual earnings (EBITDA): -81.71M vs. RYTM (-159.11M). TARS has more cash in the bank: 381M vs. RYTM (291M). RYTM has less debt than TARS: RYTM (4.19M) vs TARS (72.4M). TARS has higher revenues than RYTM: TARS (296M) vs RYTM (156M).
RYTMTARSRYTM / TARS
Capitalization6.4B3.07B208%
EBITDA-159.11M-81.71M195%
Gain YTD74.92035.109213%
P/E RatioN/AN/A-
Revenue156M296M53%
Total Cash291M381M76%
Total Debt4.19M72.4M6%
FUNDAMENTALS RATINGS
RYTM: Fundamental Ratings
RYTM
OUTLOOK RATING
1..100
75
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
22
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
42
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RYTMTARS
RSI
ODDS (%)
Bearish Trend 2 days ago
77%
Bearish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
84%
Momentum
ODDS (%)
Bearish Trend 2 days ago
73%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
77%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 8 days ago
75%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
67%
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RYTM
Daily Signal:
Gain/Loss:
TARS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCAEX5.320.03
+0.57%
Gabelli Equity Income A
FWGIX77.590.33
+0.43%
American Funds Capital World Gr&Inc F3
TMCAX12.360.03
+0.24%
RBC SMID Cap Growth A
PSOAX26.78N/A
N/A
JPMorgan Small Cap Value A
HMDCX25.38-0.07
-0.28%
Hartford MidCap C

RYTM and

Correlation & Price change

A.I.dvisor indicates that over the last year, RYTM has been loosely correlated with OCUL. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if RYTM jumps, then OCUL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RYTM
1D Price
Change %
RYTM100%
-1.94%
OCUL - RYTM
40%
Loosely correlated
+2.41%
WVE - RYTM
40%
Loosely correlated
-4.20%
XENE - RYTM
40%
Loosely correlated
-0.60%
IDYA - RYTM
39%
Loosely correlated
-0.19%
TARS - RYTM
39%
Loosely correlated
-1.10%
More

TARS and

Correlation & Price change

A.I.dvisor indicates that over the last year, TARS has been loosely correlated with XENE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if TARS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TARS
1D Price
Change %
TARS100%
-1.10%
XENE - TARS
41%
Loosely correlated
-0.60%
OCUL - TARS
40%
Loosely correlated
+2.41%
MIRM - TARS
40%
Loosely correlated
-0.76%
ERAS - TARS
40%
Loosely correlated
+12.29%
RYTM - TARS
38%
Loosely correlated
-1.94%
More